2022

1. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era

   Annals of Hematology, Vol. 101, Núm. 1, pp. 59-67

2. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

   Blood Advances, Vol. 6, Núm. 24, pp. 6219-6227